ID4Pharma
Private Company
Funding information not available
Overview
ID4Pharma is a private, preclinical-stage biotech developing first-in-class, p62/SQSTM1-targeted small molecule therapies for multiple myeloma. Its lead asset, Sequesta™, has completed FDA IND-enabling studies, demonstrating high efficacy and a favorable safety profile in preclinical models, and is now advancing toward human clinical trials. The company, led by a team with deep pharmaceutical industry and FDA experience, has been awarded a $2.3 million SBIR Fast Track grant and is actively seeking strategic partnerships and investment to fund Phase IB/IIA trials.
Technology Platform
TargetHunter Intelligent Drug R&D Platform: an integrated medicinal chemistry/biology discovery platform powered by big-data machine/deep learning system pharmacology computing (TargetHunter), bioassays, and medicinal chemistry knowledge.
Opportunities
Risk Factors
Competitive Landscape
The multiple myeloma therapeutic landscape is highly competitive, dominated by major pharmaceutical companies with proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and newer CAR-T cell and bispecific antibody therapies. ID4Pharma's differentiation lies in targeting the novel p62 pathway, aiming to address drug resistance—a key limitation of current standards of care. It will compete against other novel small molecules and next-generation biologics in development.